Test

The chart shows the growth of an initial investment of $10,000 in Test, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends. The portfolio is rebalanced Every 3 months.

Based on dividend-adjusted daily data since Mar 7, 2025, Test's average daily return is +0.04%, while the average monthly return is +0.81%. At this rate, an investment would double in approximately 7.2 years.

Historically, 63% of months were positive and 38% were negative. The best month was Feb 2026 with a return of +4.0%, while the worst month was Mar 2026 at -2.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 2 months.

On a daily basis, Test closed higher 56% of trading days. The best single day was Apr 9, 2025 with a return of +1.6%, while the worst single day was Apr 4, 2025 at -2.5%.

Test has an annualized alpha of 6.70%, beta of 0.18, and R2 of 0.15 versus S&P 500 Index. Calculated based on daily prices since March 07, 2025.

• This portfolio captured 29.06% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1.42%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.18 may look defensive, but with R2 of 0.15 this portfolio is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this portfolio's risk.
• R2 of 0.15 means this portfolio moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Test has an expense ratio of 0.86%, placing it in the medium range. Below, you can find the expense ratios of the portfolio's funds side by side and easily compare their relative costs.

Test ranks 33 for risk / return — below 33% of Portfolios on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below presents risk-adjusted performance metrics for Test and compares them with S&P 500 Index.

The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Test Sharpe ratios as of Jun 9, 2026 (values are recalculated daily):

• 1-Year: 1.73
• All Time: 1.30

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

Compared to the broad market, where average Sharpe ratios range from 1.63 to 2.51, this portfolio's current Sharpe ratio falls between the 25th and 75th percentiles. This indicates that its risk-adjusted performance is in line with the majority of portfolios, suggesting a balanced approach to risk and return—likely suitable for a wide range of investors.

The chart below shows the rolling Sharpe ratio of Test compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.

Test provided a 4.39% dividend yield over the last twelve months.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Test. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Test was 5.08%, occurring on Apr 10, 2025. Recovery took 68 trading sessions.

The current Test drawdown is 3.18%.

The chart below shows the rolling one-month volatility.